Sarepta Moves Closer to Full Approval for Two Key Duchenne Muscular Dystrophy Drugs Sarepta DMD drugs AMONDYS 45 and VYONDYS 53 near full FDA approval; decision due Feb 2027. Credit: Cassandra Klos/Bloomberg Subscribe now Already have an account? Sign in.
